Beam Therapeutics Inc.BEAMEarnings & Financial Report
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
BEAM Q4 FY2025 Key Financial Metrics
Revenue
$114.1M
Gross Profit
N/A
Operating Profit
$-17.4M
Net Profit
$244.3M
Gross Margin
N/A
Operating Margin
-15.3%
Net Margin
214.1%
YoY Growth
279.5%
EPS
$2.53
Beam Therapeutics Inc. Q4 FY2025 Financial Summary
Beam Therapeutics Inc. reported revenue of $114.1M (up 279.5% YoY) for Q4 FY2025, with a net profit of $244.3M (up 370.4% YoY) (214.1% margin).
Key Financial Metrics
| Total Revenue | $114.1M |
|---|---|
| Net Profit | $244.3M |
| Gross Margin | N/A |
| Operating Margin | -15.3% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Beam Therapeutics Inc. Q4 FY2025 revenue of $114.1M breaks down across 2 segments, led by Pfizer at $109.1M (95.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pfizer | $109.1M | 95.6% |
| Other | $5.0M | 4.4% |
Beam Therapeutics Inc. Quarterly Revenue & Net Profit History
Beam Therapeutics Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $114.1M | +279.5% | $244.3M | 214.1% |
| Q4 FY2023 | $316.2M | +1478.0% | $142.8M | 45.2% |
Income Statement
| Q4 2023 | Q4 2025 | |
|---|---|---|
| Revenue | $316.2M | $114.1M |
| YoY Growth | 1478.0% | 279.5% |
Balance Sheet
| Q4 2023 | Q4 2025 | |
|---|---|---|
| Assets | $1.46B | $1.48B |
| Liabilities | $478.4M | $242.8M |
| Equity | $981.3M | $1.24B |
Cash Flow
| Q4 2023 | Q4 2025 | |
|---|---|---|
| Operating CF | $135.1M | $-83.3M |